| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 935 | 3.343 | 1.414 | 3.205 | 8.028 | 1.794 | - | - | - |
| Total Income - EUR | - | 935 | 3.968 | 1.414 | 3.205 | 8.077 | 1.794 | - | - | - |
| Total Expenses - EUR | - | 1.997 | 5.005 | 7.333 | 2.765 | 5.997 | 1.038 | - | - | - |
| Gross Profit/Loss - EUR | - | -1.062 | -1.038 | -5.920 | 440 | 2.080 | 756 | - | - | - |
| Net Profit/Loss - EUR | - | -1.090 | -1.157 | -5.920 | 377 | 1.756 | 702 | - | - | - |
| Employees | - | 0 | 0 | 0 | 1 | 0 | 0 | - | - | - |
Check the financial reports for the company - Crispharma Plus Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
| Current Assets | - | 5.165 | 10.293 | 10.450 | 12.517 | 6.482 | 5.413 | - | - | - |
| Inventories | - | 3.233 | 7.486 | 6.850 | 5.617 | 4.036 | 3.310 | - | - | - |
| Receivables | - | 1.921 | 2.439 | 2.977 | 6.324 | 1.435 | 1.455 | - | - | - |
| Cash | - | 10 | 368 | 623 | 576 | 1.012 | 649 | - | - | - |
| Shareholders Funds | - | -1.045 | -2.184 | -8.064 | -7.531 | -5.632 | -4.805 | - | - | - |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | - | - | - |
| Debts | - | 6.210 | 12.477 | 18.515 | 20.047 | 12.114 | 10.218 | - | - | - |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4799 - 4799" | |||||||||
| CAEN Financial Year |
4799
|
|||||||||
Comments - Crispharma Plus Srl